PURPOSE: Hepatopulmonary syndrome (HPS) is a progressive, deteriorating complication of end-stage liver disease (ESLD) that occurs in 13-47% of liver transplant candidates. Although LT is the only therapeutic option for HPS, it has a high morbidity and mortality, especially in patients with severe hypoxemia before transplantation, but the course of HPS after living donor liver transplantation (LDLT), especially for biliary atresia (BA) patients is not well established. PATIENTS AND METHODS: The present study evaluated 122 patients who received an LDLT for BA and of these, 3 patients had HPS at the time of LDLT in a single-center series. RESULTS: Two patients of the HPS patients them had biliary and/or vascular complications, but they recovered uneventfully with interventional treatment. None of the patients required supplemental oxygen and had no residual cardiopulmonary abnormalities at a follow-up of more than 24 months. CONCLUSION: Although a series of three patients is too small for definitive conclusion and further investigations must be conducted, pediatric LDLT can be a favorable therapeutic option for HPS.
PURPOSE:Hepatopulmonary syndrome (HPS) is a progressive, deteriorating complication of end-stage liver disease (ESLD) that occurs in 13-47% of liver transplant candidates. Although LT is the only therapeutic option for HPS, it has a high morbidity and mortality, especially in patients with severe hypoxemia before transplantation, but the course of HPS after living donor liver transplantation (LDLT), especially for biliary atresia (BA) patients is not well established. PATIENTS AND METHODS: The present study evaluated 122 patients who received an LDLT for BA and of these, 3 patients had HPS at the time of LDLT in a single-center series. RESULTS: Two patients of the HPS patients them had biliary and/or vascular complications, but they recovered uneventfully with interventional treatment. None of the patients required supplemental oxygen and had no residual cardiopulmonary abnormalities at a follow-up of more than 24 months. CONCLUSION: Although a series of three patients is too small for definitive conclusion and further investigations must be conducted, pediatric LDLT can be a favorable therapeutic option for HPS.
Authors: N Taniai; M Onda; T Tajiri; K Akimaru; H Yoshida; Y Mamada; S Yokomuro; S Mineta; M Yoshioka; A Hirakata; Y Kawano; Y Mizuguchi Journal: Transplant Proc Date: 2002-11 Impact factor: 1.066
Authors: H Egawa; M Kasahara; Y Inomata; S Uemoto; K Asonuma; S Fujita; T Kiuchi; M Hayashi; T Yonemura; M Yoshibayashi; Y Adachi; J A Shapiro; K Tanaka Journal: Transplantation Date: 1999-03-15 Impact factor: 4.939
Authors: Bao Luo; Lichuan Liu; Liping Tang; Junlan Zhang; Cecil R Stockard; William E Grizzle; Michael B Fallon Journal: J Hepatol Date: 2003-05 Impact factor: 25.083
Authors: Michael J Krowka; M Susan Mandell; Michael A E Ramsay; Steve M Kawut; Michael B Fallon; Cosme Manzarbeitia; Manuel Pardo; Paul Marotta; Shinji Uemoto; Markus P Stoffel; Joanne T Benson Journal: Liver Transpl Date: 2004-02 Impact factor: 5.799
Authors: Eric A Collisson; Hamid Nourmand; Mark H Fraiman; Christopher B Cooper; Paul E Bellamy; Douglas G Farmer; John M Vierling; Rafik M Ghobrial; Ronald W Busuttil Journal: Liver Transpl Date: 2002-10 Impact factor: 5.799